Impact of Direct‐Acting Antiviral Treatment for Hepatitis C on Cardiovascular Diseases and Extrahepatic Cancers - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Pharmacoepidemiology and Drug Safety Année : 2022

Impact of Direct‐Acting Antiviral Treatment for Hepatitis C on Cardiovascular Diseases and Extrahepatic Cancers

Résumé

Purpose: The impact of direct-acting antivirals (DAAs) on extrahepatic complications in chronic hepatitis C (CHC) patients remains poorly described. We estimated the association of DAAs with cardiovascular events and extrahepatic cancers. Methods: The prospective ANRS CO22 HEPATHER cohort was enriched with individual data until December 2018 from the French Health Insurance Database (SNDS). CHC patients were enrolled between August 2012 and December 2015 in 32 French hepatology centers. A total of 8148 CHC adults were selected. Cardiovascular events (stroke, acute coronary syndrome, pulmonary embolism, heart failure, arrhythmias and conduction disorders [ACD], peripheral arterial disease [PAD]) and extrahepatic solid cancers were derived from the SNDS. Associations between DAAs and extrahepatic events were estimated using marginal structural models, with adjustments for clinical confounders. Results: Analyses of 12 905 person-years of no DAA exposure and 22 326 person-years following DAA exposure showed a decreased risk of PAD after DAA exposure (hazard ratio [HR], 0.54; 95% CI, 0.33–0.89), a beneficial effect of DAAs on overall cardiovascular outcomes in patients with advanced fibrosis (aHR, 0.58; 95% CI, 0.42–0.79), and an increased risk of ACD (hazard ratio [HR], 1.46; 95% CI, 1.04–2.04), predominant after the first year following DAA initiation. There was no association between DAAs and extrahepatic cancer risk (HR, 1.23; 95% CI, 0.50–3.03). Conclusions: DAAs were not associated with extrahepatic cancer development or reduction. They were associated with a decreased risk of PAD and an increased risk of ACD, supporting long-term cardiac monitoring after DAA therapy.
Fichier principal
Vignette du fichier
Pharmacoepidemiology and Drug - 2022 - Lam - Impact of Direct%E2%80%90Acting Antiviral Treatment for Hepatitis C on Cardiovascular.pdf (714.43 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03883026 , version 1 (02-12-2022)

Identifiants

Citer

Laurent Lam, Hélène Fontaine, Nathanael Lapidus, Céline Dorival, Jonathan Bellet, et al.. Impact of Direct‐Acting Antiviral Treatment for Hepatitis C on Cardiovascular Diseases and Extrahepatic Cancers. Pharmacoepidemiology and Drug Safety, In press, ⟨10.1002/pds.5576⟩. ⟨hal-03883026⟩
30 Consultations
131 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More